Nexstim

3,71EUR +3,06 %
5.051 investorer følger denne virksomhed
P/E (23e)
-20,4
EV/EBIT (23e)
-22,68
P/B (23e)
9,82
Udbytteafkast, % (23e)
-
Kursmål
4.50 EUR
Anbefaling
Akkumulér
Opdateret
28.2.2023
First North Finland
NXTMH
Daglig lav / høj pris
3,65 / 3,75 EUR
Markedsværdi
25,1 mio. EUR
Aktieomsætning
34,75 t EUR
Volumen
9,4 t
Risiko og anbefaling
HøjRisikoLav
SælgAnbefalingKøb

Resultatopgørelse

20192020202120222023e2024e2025e2026e
Omsætning3,354,116,409,537,459,9512,4014,67
vækst-%25,30 %22,88 %55,51 %48,91 %-21,81 %33,54 %24,65 %18,31 %
EBITDA-6,22-2,97-1,011,32-0,770,782,523,84
EBIT (adj.)-6,52-3,33-1,450,84-1,220,271,913,32
EBIT-6,52-3,33-1,450,84-1,220,271,913,32
Overskud før skat-6,78-4,12-0,731,31-1,320,171,813,19
Netto indkomst-6,78-4,12-0,831,31-1,320,171,813,19
EPS (adj.)-0,11-0,01-0,110,18-0,180,020,250,44
vækst-%-201,10 %938,22 %76,02 %
Udbytte0,000,000,000,000,000,000,000,22
Udbytte ratio50,00 %

Profitability and return on capital

20192020202120222023e2024e2025e2026e
EBITDA-%-185,72 %-72,09 %-15,77 %13,80 %-10,37 %7,84 %20,36 %26,19 %
EBIT-% (adj.)-194,66 %-81,01 %-22,70 %8,79 %-16,41 %2,76 %15,43 %22,63 %
EBIT-%-194,66 %-81,01 %-22,70 %8,79 %-16,41 %2,76 %15,43 %22,63 %
ROE1.312,02 %373,11 %-96,01 %35,97 %-38,80 %6,16 %47,36 %50,41 %
ROI-96,48 %-73,15 %-27,22 %11,42 %-15,05 %3,14 %21,66 %37,27 %

Værdiansættelse

20192020202120222023e2024e2025e2026e
Share price (EUR)2,277,664,784,113,713,713,713,71
Aktier62,79439,627,277,277,277,277,277,27
Markedsværdi142,343.366,1934,7629,8926,9826,9826,9826,98
Enterprise value144,353.367,7833,4628,9327,7227,6625,9022,81
EV/S43,11818,615,233,043,722,782,091,55
EV/EBITDA---22,00-35,4810,265,94
EV/EBIT (adj.)---34,57-100,7313,546,87
EV/EBIT---34,57-100,7313,546,87
P/E (adj.)---22,85-154,5014,888,45
P/E---22,85-154,5014,888,45
P/B--10,857,349,829,235,703,40
P/S42,51818,235,433,143,622,712,181,84
Udbytteprocent5,91 %
Equity ratio-9,66 %-23,54 %31,90 %39,84 %23,49 %22,80 %34,17 %53,33 %
Gearing ratio-271,69 %-108,13 %-40,62 %-23,39 %27,11 %23,40 %-22,68 %-52,64 %

Kvartalsdata

Q1/22Q2/22Q3/22Q4/222022Q1/23eQ2/23eQ3/23eQ4/23e
Omsætning6,792,739,533,174,27
EBITDA2,53-1,221,32-0,860,09
EBIT2,33-1,490,84-1,08-0,14
Overskud før skat3,21-1,901,31-1,13-0,19
Netto indkomst3,21-1,901,31-1,13-0,19
Publisher
Nexstim reported results on the use of accelerated iTBS protocol

On Thursday, Nexstim reported results from a pilot study on the use of accelerated iTBS protocol in treatment of severe depression with Nexstim NBT® System on 20 patients. At the end of the 12-week follow-up period, 25% of patients benefited significantly (remission) from the treatment. We do not think one can draw far-reaching conclusions from a narrow study, but the figure is equal to or lowish compared to results from other similar studies.

Analytikerkommentar09.06.2023 af Antti Siltanen
Publisher
Nexstim received marketing authorization for its NBS6 product also in Europe

On Wednesday, Nexstim announced it had received MDR certification (Medical Device Regulation) for its NBS6 product and quality management system. This certification enables selling the new product generation NBS6 in the EU. The company already reported it had received FDA approval for the same product version for the treatment of Major Depressive Disorder. Regulatory approvals are expected positive news, which at this stage have no impact on our estimates

Analytikerkommentar19.05.2023 af Antti Siltanen